News und Analysen
Best Buy: Johnson & Johnson, Pfizer, or Gilead Sciences?
Remember the old game show "Let's Make a Deal"? It was originally hosted by the recently deceased Monty Hall, and its current iteration is hosted by comedian Wayne Brady. Contestants can choose....
Best Buy: Johnson & Johnson, Pfizer, or Gilead Sciences?
Remember the old game show "Let's Make a Deal"? It was originally hosted by the recently deceased Monty Hall, and its current iteration is hosted by comedian Wayne Brady. Contestants can choose....
This U.S. Marijuana Stock Is Arguably the Best on the Market -- and It's Dirt Cheap
What's the best U.S. marijuana stock on the market right now?Including only the U.S. in the question excludes several of the top candidates, such as U.K.-based GW Pharmaceuticals (NASDAQ: GWPH)....
The Long-Term Trend That Makes Intuitive Surgical an Awesome Buy
This year is turning out to be one of the best ever for Intuitive Surgical (NASDAQ: ISRG). Shares of the robotic surgical systems maker are up more than 60% so far in 2017. There hasn't been one....
Pfizer Exposes the Sordid Underbelly of Drug Prices
Johnson & Johnson's (NYSE: JNJ) one of the largest drugmakers in the world, and according to a lawsuit Pfizer (NYSE: PFE) has filed, it's leveraging its size to negotiate contracts that....
Pfizer Exposes the Sordid Underbelly of Drug Prices
Johnson & Johnson's (NYSE: JNJ) one of the largest drugmakers in the world, and according to a lawsuit Pfizer (NYSE: PFE) has filed, it's leveraging its size to negotiate contracts that....
Better Buy: Exelixis, Inc. vs. Immunogen, Inc.
It's been a really good year for Exelixis (NASDAQ: EXEL). The biotech's share price has jumped more than 60% so far in 2017, thanks to continued momentum for its kidney cancer drug Cabometyx. But....
3 Biotech Stocks That Soared This Week: Are They Buys?
There's nothing like good results from a clinical study to light a fire beneath a biotech stock. That's what has happened with several biotechs over the last few days.Madrigal Pharmaceuticals....
The Unusual Reason PTC Therapeutics, Inc. Is Bouncing Back Today
Despite a 10-1 advisory committee vote against PTC Therapeutics, Inc.'s (NASDAQ: PTCT) experimental Duchenne muscular dystrophy (DMD) drug Thursday, the stock is on the rise on Friday. A slight....
1 Great Biotech Stock You Have Never Heard Of
About 90% of drug candidates that enter clinical trials never make it to market. That brutal fact makes the small-cap biotech sector a tough place for investors to put their money to work.However,....
1 Great Biotech Stock You Have Never Heard Of
About 90% of drug candidates that enter clinical trials never make it to market. That brutal fact makes the small-cap biotech sector a tough place for investors to put their money to work.However,....
These 3 Stocks Look Expensive, but Are Actually Cheap
Stocks with above average price-to-earnings (P/E) ratios, or those trading near their 52-week highs, aren't always expensive. The true test of whether a stock is cheap or not, after all, is the....
How Good Is AbbVie's Humira Deal With Amgen?
One major cloud that has been hanging over AbbVie (NYSE: ABBV) is how long the company will be able to hold off biosimilar competition for its top-selling drug Humira. Amgen (NASDAQ: AMGN) won FDA....
How Good Is AbbVie's Humira Deal With Amgen?
One major cloud that has been hanging over AbbVie (NYSE: ABBV) is how long the company will be able to hold off biosimilar competition for its top-selling drug Humira. Amgen (NASDAQ: AMGN) won FDA....
How Good Is AbbVie's Humira Deal With Amgen?
One major cloud that has been hanging over AbbVie (NYSE: ABBV) is how long the company will be able to hold off biosimilar competition for its top-selling drug Humira. Amgen (NASDAQ: AMGN) won FDA....
Why BlackBerry, AbbVie, and bluebird bio Jumped Today
Thursday was a quiet day on Wall Street, with major benchmarks remaining close to the unchanged level. Sentiment among market participants remained relatively favorable in the aftermath of the....
Why BlackBerry, AbbVie, and bluebird bio Jumped Today
Thursday was a quiet day on Wall Street, with major benchmarks remaining close to the unchanged level. Sentiment among market participants remained relatively favorable in the aftermath of the....
Why BlackBerry, AbbVie, and bluebird bio Jumped Today
Thursday was a quiet day on Wall Street, with major benchmarks remaining close to the unchanged level. Sentiment among market participants remained relatively favorable in the aftermath of the....
Better Buy: Bellicum Pharmaceuticals, Inc. vs. bluebird bio
This version of our ongoing better buy series pits two development-stage biotechs, Bellicum Pharmaceuticals (NASDAQ: BLCM) and bluebird bio (NASDAQ: BLUE), against each other. The companies have....
This Drug Pricing Scheme Could Be Making Your Medicine More Expensive
Biosimilars that are as safe and effective as expensive brand-name biologics could significantly reduce drug prices and healthcare spending, but only if they win support from insurers.....
This Drug Pricing Scheme Could Be Making Your Medicine More Expensive
Biosimilars that are as safe and effective as expensive brand-name biologics could significantly reduce drug prices and healthcare spending, but only if they win support from insurers.....
Here's Why Spectrum Pharmaceuticals, Inc. Is Surging Today
Shares of Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI), a biopharmaceutical company primarily focused on cancer and blood-based disorders, are rising in response to some surprising early stage....
Why DexCom Stock Is Getting Crushed Today
Shares of medical device company and diabetes specialist DexCom Inc. (NASDAQ: DXCM) slipped sharply Thursday morning, declining by more than 36% as of 11:50 a.m. EDT. This tumble stemmed from the....
Vertex Pharmaceuticals: The Gilead Sciences of Cystic Fibrosis?
In only a year, Vertex Pharmaceuticals (NASDAQ: VRTX) has grown from a market cap of around $20 billion to knocking on the door of a $40 billion market cap. The biotech isn't finished growing.....
Vertex Pharmaceuticals: The Gilead Sciences of Cystic Fibrosis?
In only a year, Vertex Pharmaceuticals (NASDAQ: VRTX) has grown from a market cap of around $20 billion to knocking on the door of a $40 billion market cap. The biotech isn't finished growing.....